Safety and efficacy profile of systemic corticosteroids and isotretinoin versus systemic corticosteroids alone in cutaneous lichen planus- A hospital based prospective double blind placebo controlled comparative study

Krishna Institute of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•A.Must give written consent before any treatment commenced.
•B.Must be diagnosed to be suffering from cutaneous lichen planus either by clinical examination or histopathology if required.
•C.Must have generalised lichen planus involving minimum 20% body surface area or cases of palmoplantar lichen planus
•D.Must stop any other modality of treatment, two months prior to the inclusion in study.
•E.Must be able and willing, in the view of investigator, to comply all study procedure.

•A. Patient having only oral lichen planus, genital lichen planus, nail lichen planus, follicular lichen planus, actinic lichen planus, lichen planus pigmentosus, lichen planus pemphigoides,
•B. Patient with hypersensitivity to drug or patient intolerant to the study medication.
•C. Pregnant and lactating patient.
•D. Patient with unrealistic expectations.
•E. Not willing for regular follow up.
•F. Patient with clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation.
•G. Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results.
•H. Patient having history of tuberculosis or chest X-ray showing evidence of any infective pathology.
•I. Immunocompromised patients

发起方